Introduction {#Sec1}
============

Nitric oxide was first reported to be an endogenous vasodilator in 1987 \[[@CR1]\]. Soon after this discovery, inhaled nitric oxide (iNO) was applied to treat pulmonary hypertension and various pulmonary diseases \[[@CR2],[@CR3]\]. Previous studies and clinical trials have shown that iNO possesses the therapeutic effects of selective pulmonary vasodilatation without causing systemic hypotension, and an effect on improving ventilation-perfusion mismatch \[[@CR3],[@CR4]\]. Currently, iNO has been an important treatment modality for pulmonary hypertension, acute respiratory distress syndrome (ARDS), and pediatric hypoxemic respiratory failure \[[@CR5]-[@CR7]\].

Cumulative data from physiological studies and clinical trials suggest that iNO therapy has a good safety profile \[[@CR8]-[@CR10]\], and that its potential adverse effects, including methemoglobinemia, inhibition of platelet aggregation and systemic vasodilatation, are usually clinically insignificant \[[@CR8],[@CR11],[@CR12]\]. However, a safety concern about renal dysfunction for nitric oxide inhalation was reported in a meta-analysis designed to evaluate the efficacy of iNO in ARDS \[[@CR13]\]. This finding contradicts earlier evidence that iNO has favorable effects on renal and splanchnic perfusion \[[@CR8]\]. In addition, this adverse effect, as a class effect of iNO therapy, was not observed in non-ARDS populations. These contrasting findings warrant further investigation to clarify the association between iNO and the risk of renal dysfunction in patients with and without ARDS. Therefore, we conducted this systematic review and meta-analysis to ascertain the risk of acute kidney injury (AKI) in iNO therapy and to investigate whether the risk varies among different patient populations.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

This systematic review was conducted using an a priori published protocol submitted to the PROSPERO website (Registration number CRD42013005731) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria \[[@CR14]\]. No institutional review board approval or consents were needed for this systematic review because it evaluated published studies. We searched MEDLINE via the NCBI Entrez system and Cochrane Central Register of Controlled Trials up to 25 September 2014. Bibliographies of retrieved studies and recent review articles were also screened to identify additional trials. Both keywords and MeSH terms searches were used to identify relevant citations. The search terms were "inhaled nitric oxide" AND "randomized controlled trial", and MeSH terms were "Nitric Oxide/therapeutic use" \[Mesh\] AND "Randomized Controlled Trial" \[Publication Type\]. There were no language restrictions. Details of our search strategy are shown in the online appendix (see Additional file [1](#MOESM1){ref-type="media"}). The eligible studies were parallel randomized controlled trials (RCTs) comparing patients who did and did not receive iNO therapy. The exclusion criteria included crossover trials and studies not reporting AKI in the results.

Study selection and data extraction {#Sec4}
-----------------------------------

Two investigators (SYR and TMH) screened studies for inclusion and independently extracted data from the included studies. Any disagreements were resolved by discussion. A standardized recording form was used for data extraction.

Assessment of risk of bias {#Sec5}
--------------------------

Quality assessment of these studies was done using the Cochrane Collaboration tool for assessing the risk of bias \[[@CR15]\]. We assessed the risk of bias associated with random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective outcome reporting, and other bias. Two investigators (SYR and TMH) independently assessed the risk of bias in the individual studies, and discrepancies were resolved by consensus.

Outcome measures {#Sec6}
----------------

The primary outcome of interest was AKI as defined in the individual studies regardless of the severity of injury. The secondary outcome was AKI requiring renal replacement therapy (RRT). Risk ratio (RR) was used as a measurement of association in the analysis.

Stratified analysis {#Sec7}
-------------------

Stratified analysis by study population was performed to investigate whether the risk of iNO-associated renal dysfunction varied among different patient populations. To test the dose-response relationship between iNO and the risk of renal dysfunction, stratified analysis by duration and dosage of iNO therapy was also performed.

Data synthesis {#Sec8}
--------------

Outcome measures were pooled using a random-effects model with the inverse variance method because of anticipated heterogeneity among the included studies. We analyzed data by intention-to-treat analysis and calculated the point estimates and 95% CI of the summary effect. When one arm of a study contained no events, 0.5 was added to all cells of the two-by-two table \[[@CR16]\]. Sensitivity analysis was performed to check the robustness of the effect estimate using different data synthesis models. The Peto method was used in the sensitivity analysis because of its advantage of a less biased estimate for summary effect in the settings of sparse data and imbalance of trial size \[[@CR17]\]. Because the Peto method can only be used to calculate odds ratios (ORs), we also calculated ORs using a random-effects model to compare the effect sizes obtained by these two methods. Heterogeneity was explored using the *Q*-statistic and I^2^. Heterogeneity was considered low, moderate, and high according to I^2^ values of \<25%, 25 to 50% and \>50%, respectively \[[@CR18]\]. Publication bias was evaluated by a funnel plot of standard error versus RR based on the primary outcome, and with Egger's test \[[@CR19]\]. For all analyses, a two-sided *P*-value \<0.05 was considered to be statistically significant. The data were analyzed using Stata software, version 11 (StataCorp, Texas, USA).

Results {#Sec9}
=======

Literature search and study characteristics {#Sec10}
-------------------------------------------

Through the electronic searches and from references, 252 citations were identified. According to our predefined inclusion and exclusion criteria, 10 RCTs involving a total of 1,363 patients were included in the final analysis \[[@CR12],[@CR20]-[@CR28]\]. To calculate the risk for incident AKI, 26 patients were excluded from the analysis because they had received hemodialysis before the enrollment of trials. The number of studies evaluated at each stage of the literature review is shown in Figure [1](#Fig1){ref-type="fig"}. Quality assessment (see Additional file [2](#MOESM2){ref-type="media"}) of the included studies suggested a low risk of bias, except for one study which was published with an abstract \[[@CR21]\].Figure 1**Study flow through this systematic review.** RCT, randomized controlled trial.

The characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. The publication year ranged from 1998 to 2014, and included four studies on patients with ARDS, four studies on patients undergoing surgery, one study on neonates with hypoxemic respiratory failure, and one study on patients with sepsis. The administered dose and duration of iNO varied largely among these studies. In the ARDS trials, the dose of iNO shifted from a titrated dose of 1 to 40 ppm in the 1990s to a fixed dose of 5 ppm in the latest trial \[[@CR12],[@CR23]\]. The treatment duration was longer in the ARDS studies (\>7 days) than in the non-ARDS studies (≤7 days).Table 1**Details of the included randomized controlled trialsStudy (year)CountryStudy populationProtocol of iNO therapyMean iNO dosageAge, yearsDefinition of acute kidney injury (AKI)Number of AKI/number of casesiNOControl**Dellinger (1998) \[[@CR12]\]USAARDS1.25, 5.0, 20.0, 40.0, or 80.0 ppm iNO for 28 days or till FiO~2~ \< 0.521 ppm48Creatinine \>2 mg/dL20/1207/57Creatinine ≥3.5 mg/dL13/1205/57Lundin (1999) \[[@CR20]\]11 European countriesARDS1 to 40 ppm iNO at the lowest effective dose for up to 30 days or until an end point was reached9 ppm57Creatinine \>3.4 mg/dL or RRT28/8012/74Incident RRT23/8410/79Kinsella (1999) \[[@CR22]\]USANeonate hypoxemic respiratory failure5 ppm for 7 days5 ppm27 weeksRenal failure2/482/32Payen (1999) \[[@CR21]\]EuropeARDS10 ppm till PF \>250, median 5 days10 ppmNot reportedRRT33/9826/105Taylor (2004) \[[@CR23]\]USAARDS5 ppm until 28 days, discontinuation of assisted breathing, or death5 ppm50Creatinine ≥3 mg/dL12/1928/193Creatinine ≥3.5 mg/dL10/1926/193Perrin (2006) \[[@CR24]\]FranceLung transplantation20 ppm for 12 h20 ppm35RRT1/151/15Potapov (2011) \[[@CR26]\]USA and GermanyCardiac surgery40 ppm for 48 h40 ppm56RRT10/738/77Fernandes (2011) \[[@CR25]\]BrazilCardiac surgery10 ppm for 48 h10 ppm46Urine output \<0.3 ml/kg/h0/141/15Lang (2014) \[[@CR28]\]USALiver transplantation80 ppm during the operative phase80 ppm56Renal dysfunction3/407/40Trzeciak (2014) \[[@CR27]\]USASepsis40 ppm for 6 h40 ppm59RRT2/261/23AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; iNO, inhaled nitric oxide; FiO~2~: inspired oxygen fraction; PF: PaO~2~/FiO~2~ ratio; RRT: renal replacement therapy.

Reporting of renal dysfunction {#Sec11}
------------------------------

Renal dysfunction in these trials was usually defined as an excess of creatinine level to a predefined level or the need for renal replacement therapy (Table [1](#Tab1){ref-type="table"}). Among these trials, three reported the data of two different definitions of renal dysfunction. Notably, many clinical trials of iNO were excluded from this systematic review due to a lack of data on renal adverse effects, especially in the pediatric studies. Bleeding and neurological complications were the main concerns for the pediatric patients, and data on renal dysfunction were rarely reported in the safety outcomes.

Quantitative data synthesis {#Sec12}
---------------------------

For the primary outcome of AKI with any severity (Figure [2](#Fig2){ref-type="fig"}), the pooled effect from 10 studies showed that iNO therapy significantly increased the risk of AKI with an RR of 1.40 (95% CI, 1.06 to 1.83, *P* = 0.02, *I*^2^ = 0%). The study by Payen \[[@CR21]\] accounted for 39% of meta-analysis weight but was only published with an abstract. After omitting this influential study, the effect estimate remained similar (RR, 1.42, 95% CI, 1.003 to 2.01, *P* = 0.048, *I*^2^ = 0%). The statistical heterogeneity was low among the analyses.Figure 2**Forest plot for the risk of acute kidney injury.** iNO, inhaled nitric oxide.

For the endpoint of AKI requiring renal replacement therapy (Figure [3](#Fig3){ref-type="fig"}), iNO also increased the risk with a RR of 1.51 (95% CI, 1.09 to 2.11, *P* = 0.01, *I*^2^ = 0%). The effect estimate became larger after we omitted the influential study by Payen (RR, 1.76, 95% CI, 1.05 to 2.93, *P* = 0.03, *I*^2^ = 0%).Figure 3**Forest plot for the risk of initiating renal replacement therapy.** iNO, inhaled nitric oxide.

Due to the presence of sparse data and imbalance of trial size, sensitivity analysis was performed to evaluate the influence of data synthesis methods on the estimate of summary effect. The effect estimate by the Peto method was similar to that obtained by the primary analysis with a random-effects model (Table [2](#Tab2){ref-type="table"}).Table 2**Sensitivity analysis by different data synthesis methodsOutcome measuresNumber of studies (number of patients)Statistical modelEffect size (95% CI)*P*** **-value (test for effect)Heterogeneity**Acute kidney injury10 (1337)RR, random-effects1.40 (1.06 to 1.83)0.02*I* ^2^ = 0%OR, random-effects1.50 (1.07 to 2.09)0.02*I* ^2^ = 0%OR, Peto1.48 (1.07 to 2.05)0.02*I* ^2^ = 0%Initiation of renal replacement therapy5 (595)RR, random-effects1.51 (1.09 to 2.11)0.01*I* ^2^ = 0%OR, random-effects1.73 (1.13 to 2.65)0.01*I* ^2^ = 0%OR, Peto1.73 (1.14 to 2.41)0.01*I* ^2^ = 0%RR, risk ratio; OR, odds ratio.

Figure [4](#Fig4){ref-type="fig"} shows a funnel plot based on the primary outcome. The asymmetry of the funnel plot on visual inspection implied a lack of studies in which iNO increased the risk of AKI. This suggests that the pooled effect from the current data may underestimate the effect size of the risk. However, the statistical test for publication bias, Egger's test (*P* = 0.33), did not reach statistical significance.Figure 4**Funnel plot based on the primary outcome.**

The risk of AKI associated with iNO therapy varied among the different populations (Table [3](#Tab3){ref-type="table"}). The risk was significantly increased in the patients with ARDS (RR, 1.55, 95% CI, 1.15 to 2.09, *P* = 0.005), but not in patients without ARDS (RR, 0.9, 95%CI, 0.49 to 1.67, *P* = 0.75). Among the patients with ARDS, the risk difference for AKI between iNO and control groups was 0.067 (95% CI, 0.000 to 0.135, *P* = 0.05, *I*^2^ = 50%), and the number needed-to-harm to cause one additional AKI was 15.Table 3**Subgroup analysis by study populationSubgroupsNumber of studies (number of patients)Risk ratio of AKI (95% CI)*P*** **-value (test for effect)Heterogeneity**ARDS4 (919)1.55 (1.15 to 2.09)0.005*I* ^2^ = 0%Non-ARDS6 (418)0.90 (0.49 to 1.67)0.75*I* ^2^ = 0%Surgery4 (289)0.89 (0.45 to 1.75)0.73*I* ^2^ = 0%Sepsis1 (49)1.77 (0.17 to 18.26)0.63Not applicablePediatric hypoxemic respiratory failure1 (80)0.67 (0.10 to 4.49)0.68Not applicableAKI, acute kidney injury; ARDS, acute respiratory distress syndrome.

To test the dose-response relationship between iNO and the risk of AKI, we performed stratified analysis by duration and dosage of iNO therapy. Prolonged use of iNO (\>7 days) significantly increased the risk of AKI (RR, 1.55, 95% CI, 1.15 to 2.09, *P* = 0.005, four studies), whereas short-term use did not (RR, 0.90, 95% CI, 0.49 to 1.67, *P* = 0.75, six studies). Notably, the four studies involving the prolonged use of iNO are all ARDS studies. Table [4](#Tab4){ref-type="table"} summarizes the risk of renal dysfunction for different iNO exposure levels. We classified the included studies into three groups according to the cumulative dose in the stratified analysis. High cumulative dose of iNO significantly increased the risk of renal dysfunction but medium and low cumulative doses did not (Table [4](#Tab4){ref-type="table"}). Figure [5](#Fig5){ref-type="fig"} depicts the relationship between the risk of renal dysfunction and cumulative dose of iNO. Visual inspection suggested a possible association between the cumulative dose and risk of renal dysfunction but statistical test by meta-regression analysis was not significant due to small sample size (*P* = 0.10).Table 4**Dose-response relationship between inhaled nitric oxide and the risk of acute kidney injuryCumulative dose of inhaled nitric oxideNumer of studies (number of patients)Risk ratio of AKI (95% CI)*P*** **-value (test for effect)HeterogeneityReferences**Low2 (109)0.56 (0.11 to 2.86)0.49*I* ^2^ = 0%\[[@CR22],[@CR25]\]Medium3 (159)0.64 (0.23 to 1.81)0.40*I* ^2^ = 0%\[[@CR24],[@CR27],[@CR28]\]High5 (1069)1.52 (1.14 to 2.02)0.004*I* ^2^ = 0%\[[@CR12],[@CR20],[@CR21],[@CR23],[@CR26]\]AKI, acute kidney injury.Figure 5**Bubble plot with fitted meta-regression line depicting the relationship between the risk of renal dysfunction and cumulative dose of inhaled nitric oxide (Ino).**

Discussion {#Sec13}
==========

This meta-analysis updated the evidence on the renal safety of iNO therapy in ARDS and non-ARDS populations. The study suggested that the risk of iNO-associated renal dysfunction differed between ARDS and non-ARDS populations. The results showed that iNO therapy was associated with a 40% increased risk of renal dysfunction and the observed effect was mainly attributed to ARDS studies with prolonged use of iNO. If treating ARDS patients with iNO the number needed-to-harm to cause one additional AKI was 15. Sensitivity analysis by different data pooling methods revealed consistent effect estimates, and publication bias analysis suggested that the risk may be underestimated. Clinicians should be aware of this side effect when using iNO to treat patients. Our review also found that the safety outcome of renal dysfunction was not universally reported across iNO trials, especially in non-ARDS studies. We suggest that future trials of iNO should report renal safety outcomes.

The risk of renal dysfunction associated with iNO therapy was first reported in an RCT of patients with ARDS, in which iNO was found to double the risk of the need for renal replacement therapy compared with controls \[[@CR20]\]. However, this adverse effect did not raise much attention because subsequent trials of iNO reported no significant increase in the risk of renal dysfunction \[[@CR12],[@CR23]\]. In 2007, Adhikari and colleagues reported that iNO was associated with renal dysfunction in a meta-analysis \[[@CR13]\]. This meta-analysis only included ARDS trials because the primary study interest was the efficacy of iNO on ARDS \[[@CR13]\]. The strengths of our study are the comprehensive evaluations of iNO-related renal dysfunction among patients with and without ARDS, the influence of different endpoints of renal dysfunction, and the dose-response relationship. Although our analysis suggests that iNO may increase the risk of renal dysfunction, it is not clear whether the increased risk is ARDS-specific or related to prolonged use of iNO. We were unable to clarify this in study-level analysis because the ARDS studies all involved the prolonged use of iNO.

Generating awareness of the nephrotoxicity of iNO has important implications for preventing AKI in the intensive care unit. Previous studies have shown that the development of AKI significantly increased mortality in patients with ARDS \[[@CR29]\]. We suggest that intensivists should be cautious about the concurrent use of iNO with other nephrotoxic agents such as certain antibiotics, when treating ARDS. Renal function should be regularly monitored during iNO therapy to detect possible AKI early. In addition, the nephrotoxicity of iNO may partly explain why iNO therapy improves oxygenation and attenuates inflammation but confers no benefit on mortality in patients with ARDS \[[@CR3],[@CR30],[@CR31]\]. The benefits of iNO may be counterbalanced by the increased risk of renal failure, because organ failure is positively associated with mortality \[[@CR32]\].

The mechanism of iNO-related renal dysfunction remains unclear. Table [5](#Tab5){ref-type="table"} summarizes the findings of animal and physiological studies on this issue \[[@CR9],[@CR33]-[@CR38]\]. These studies all examined the effect of short-term exposure to iNO, and most reported that iNO had beneficial effects on renal function except for a swine study which reported that iNO promoted renal tubular apoptosis \[[@CR33]\]. In this swine model, renal resorption capacity was significantly blunted by iNO, and this may have led to tubular and glomerular injury by means of tubuloglomerular feedback \[[@CR33]\]. With respect to nitric oxide metabolites, nitric oxide inhalation increased serum levels of plasma cyclic guanosine monophosphate (cGMP), nitrate, and nitrite \[[@CR39]\]. These nitric oxide metabolites may play a role in AKI development owing to the effects on protein nitrosation and raising oxidative load \[[@CR40]-[@CR42]\]. In an animal model of drug-induced nephrotoxicity, elevated nitrite and nitrate levels were observed with increasing oxidative activity \[[@CR40]\]. The induced nephrotoxicity could be ameliorated by selective phosphodiesterase-5 inhibitor by suppressing oxidative activity and nitrite and nitrate levels \[[@CR40]\]. In addition, from the pathways of chemical reactions of nitric oxide in the lung, we speculate that oxidative injury caused by highly oxidant nitrogen compounds may also play a role in iNO-related kidney injury. Reactive nitrogen species such as nitrogen dioxide (NO~2~) are highly oxidative compounds that are produced when iNO mixes with high concentrations of oxygen in the alveoli \[[@CR3],[@CR11]\]. In patients with ARDS treated with iNO, the serum concentrations of NO~2~ have been positively associated with the dose of iNO administered \[[@CR12]\]. It has also been shown that systemically circulating NO~2~ may lead to cytotoxic effects on renal parenchymal cells \[[@CR43]\]. This hypothesis of oxidative injury by reactive nitrogen species may also explain why nephrotoxicity tends to develop in patients with ARDS receiving iNO therapy, as these patients usually receive high-concentration oxygen therapy, which may facilitate the production of reactive nitrogen species. Animal studies are needed to test this hypothesis.Table 5**Animal and human studies investigating the effects of inhaled nitric oxide (iNO) on the kidneysStudy (year)SpeciesProtocols of iNOMain findings**Valvini (1995) \[[@CR38]\]Human40 ppm for 3 days followed by 90 ppm for 2 days1. Inhaling 40 ppm nitric oxide would result in a daily nitrogen oxide load of about 25 mmol.2. Impairment of renal function would cause an increase in serum nitrogen oxides.Troncy (1997) \[[@CR9]\]Swine40 ppm iNOInhaled nitric oxide increased renal blood flow, glomerular filtration rate and urinary flow.Preiser (1998) \[[@CR37]\]Human1 to 20 ppm1. Renal excretion of NO~2~ ^−^ and NO~3~ ^−^ was unaltered by nitric oxide inhalation.2. Long-term nitric oxide inhalation was associated with a consistent increase in the NO~3~ ^−^ plasma concentration.Wraight (2001) \[[@CR36]\]Human40 ppm for 2 hInhaled nitric oxide may alter tubular salt and water resorbtion.Kielbasa (2001) \[[@CR35]\]Rat49 or 107 ppm iNO for 4 hHigh dose of iNO increased nitric oxide synthase III protein expression, and nitrotyrosine and phosphotyrosine immunoreactivity.Da (2007) \[[@CR34]\]Swine30 ppm iNO for 3.5 hDecreased swelling and necrosis of glomeruli.Gozdzik (2009) \[[@CR33]\]Swine40 ppm iNO for 30 h1. Transient natriuretic effect.2. Renal tubular apoptosis promotion after 30 h of iNO treatment.Göranson (2014) \[[@CR44]\]Swine30 ppm iNO for 30 hCombined therapy with iNO and intravenous steroid is associated with partial protection of kidney function.

Limitations {#Sec14}
-----------

Our study has limitations. First, the included number of studies and the number of cases in individual studies are small for the non-ARDS trials. This may have limited the statistical power of our subgroup analysis and meta-regression. Second, although the level of statistical heterogeneity was very low in all of our analyses, the heterogeneity on exposure (treatment duration and dosage of iNO) should not be overlooked. Third, death was a competing risk factor in our analysis. However, we were unable to adjust for this competing risk in study-level analysis. Individual data are needed to conduct such analyses.

Conclusion {#Sec15}
==========

This meta-analysis updated the evidence on the renal safety of iNO therapy in ARDS and non-ARDS populations. Our results suggest that iNO therapy substantially increases the risk of renal dysfunction. It remains unclear whether this markedly increased risk is disease-specific in ARDS or related to prolonged use of iNO. Further studies are needed to clarify this issue. We suggest that renal function should be monitored during iNO therapy and that future clinical trials of iNO should evaluate renal safety.

Key messages {#Sec16}
============

Previous studies have shown that iNO has a good safety profile and favorable effects on renal and splanchnic perfusion; however, iNO therapy has been reported to be associated with renal dysfunction.This meta-analysis updated the evidence regarding renal safety of iNO therapy. The study suggested that the risk of iNO-associated renal dysfunction differed between ARDS and non-ARDS populations. Nitric oxide inhalation may increase the risk of renal dysfunction, especially with prolonged use and in patients with ARDS.The safety outcome of renal dysfunction was not universally reported across iNO trials, especially in non-ARDS studies. We suggest monitoring renal function during iNO therapy, and that future trials of iNO should evaluate renal safety.

Additional files {#Sec17}
================

Additional file 1:**Details of the search strategy and results.**Additional file 2:**Quality assessment using the Cochrane risk of bias tool.**
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